

Relationship between growth velocity and change of serum insulin-like growth factor-1 (IGF-1), serum IGF binding protein-3 (IGFBP-3) concentrations, and IGFBP-3 promoter polymorphism during gonadotropin-releasing hormone agonist (GnRHa) treatment

¹Kyung Hee Yi, ²Seung Yang

¹Department of Pediatrics, Wonkwang University Sanbon Medical Center, Gunpo, Republic of Korea

²Department of Pediatrics, Hallym University College of Medicine, Seoul, Republic of Korea

Disclosure Statement

Kyung Hee Yi and Seung Yang have no relevant financial relationships to disclose or conflicts of interest to we solve.

Introductions and Objectives

- Factors affecting the better response to GnRHa treatment and final height outcome
 - Younger chronological age (CA) at puberty or start of treatment (*Paul D et al. J Clin Endocrinol Metab 1995 Feb;80:546-51*)
 - Greater height at the initial evaluation and target height (*Allali S et al. Med Sci Monit 2011;17:PH41-8*)
 - Shorter interval between the onset of the CPP and treatment (*Kauli R et al. Horm Res 1997;47:54-61*)
 - Advanced bone age (BA) and lower predicted adult height (*Adan L et al. Clin Endocrinol 2002 Mar;56:297-302*)
- Effects of sex steroids on GH-IGF-1 axis
 - Mean IGF-1 concentration in precocious children with GH deficiency was significantly above than prepubertal GH-deficient children.
 - Sex steroids increase IGF-1 levels by increasing GH production. (*Cara JF et al. J Pediatr 1989;115:64-8*)
- This study aims to investigate the effect of GnRHa on GH-IGF-1 axis and to evaluate if -202 A/C IGFBP-3 promoter polymorphism affects the growth velocity during treatment on girls with central precocious puberty (CPP).

Methods

Data was collected from 97 girls, diagnosed under 9 year of age and treated by GnRHa for at least 1 year between 2014-2015. Their body height, weight, Δ Height standard deviation score (SDS), serum IGF-1 and IGFBP-3 concentrations and bone age were measured at the start and after a year of GnRHa treatment. -202 A/C IGFBP-3 promoter polymorphism were analyzed. Possible correlations between the variables were calculated.

Results


Table 1. Characteristics of the 97 girls treated with GnRH agonist

Characteristic	At diagnosis	After a year	P-value
CA (yr)	8.5±0.5	9.6±0.5	-
BA (yr)	10.5±0.6	10.9±0.6	-
BA-CA (yr)	2.0±0.6	1.3±0.6	0.000
Height SDS	1.2±0.8	1.1±0.8	0.000
IGF-1 SDS	0.8±1.0	0.5±0.9	0.000
IGFBP-3 SDS	3.3±1.1	2.3±0.9	0.000
IGF-1/IGFBP-3	60.7±16.3	60.5±16.8	0.000
Midparental height (cm)	160.0±3.2	-	-


Values are presented as mean±standard deviation.
GnRH, gonadotropin-releasing hormone; CA, chronological age; BA, bone age; SDS, standard deviation score; IGF-1, insulin like growth factor I; IGFBP-3, insulin-like growth factor binding protein 3.

*P<0.05 compared to before the treatment.


Relationship between the changes in the IGF-1 SDS and the Height SDS




Relationship between the changes in the IGFBP-3 SDS and the Height SDS



Relationship between the changes in the IGF-1/IGFBP-3 ratio and the Height SDS




Relationship between MPH, Initial Height and the ΔHeight SDS




-202 A/C IGFBP-3 Promoter Polymorphism

AA 72 (74.2%) / AC 22 (22.7%) & CC 3 (3.1%)
C allele frequency: 14.4% (25.4% general population)



IGF-1, IGFBP3 level before and after the treatment according to allele



Conclusions

The results suggest that the growth velocity during GnRHa treatment may be related to serum IGF-1 and IGFBP-3 thus GnRHa may affect GH-IGF-1 axis. C allele in -202 A/C IGFBP-3 promoter region showed no statistically significant correlation with the height SDS, but may affect both serum IGF-1 and IGFBP-3 after the treatment.